指南与共识妇科肿瘤

ACS宫颈癌筛查指南更新:自采阴道标本HPV检测与筛查退出

Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline.
指南 / 共识 · CA Cancer J Clin · 2026-01-01

美国癌症协会(ACS)更新2020年宫颈癌筛查指南,将自采阴道标本HPV检测纳入平均风险人群筛查选项,并修订筛查退出标准:要求60岁和65岁HPV检测阴性方可退出,自采标本阴性后需3年复检。

要点

  • 25-65岁平均风险个体可选自采阴道标本HPV检测,但医生采集宫颈标本仍为首选。
  • 自采HPV检测阴性后建议3年复检,医生采集标本阴性则每5年复检。
  • 退出筛查需60岁和65岁HPV检测阴性(首选)或联合检测阴性(可接受)。

核心结论

  • 自采阴道标本HPV检测可作为平均风险25-65岁个体的可接受筛查方式,但医生采集宫颈标本仍为首选。
  • 自采HPV检测阴性后建议3年复检,而医生采集标本阴性后每5年复检。
  • 退出筛查需60岁和65岁HPV检测阴性(首选)或联合检测阴性(可接受),或连续三次细胞学阴性且末次在65岁。

研究设计与样本

  • ACS基于Enduring Consensus宫颈癌筛查与管理指南委员会的推荐,对2020年指南进行更新。

主要发现

  • 自采阴道标本可克服部分患者筛查障碍,但HPV阳性者多需额外随访步骤,长期真实世界有效性数据有限。
  • 65岁以上人群宫颈癌发病率高且现有退出标准实施不佳,故修订退出标准。
  • 自采标本仅适用于FDA批准的采集装置与HPV检测组合(临床或家庭使用)。

关键数值与推荐

  • 平均风险个体25-65岁可接受自采阴道标本HPV检测。
  • 自采HPV检测阴性后3年复检;医生采集标本阴性后5年复检。
  • 退出筛查:60岁和65岁HPV检测阴性(首选)或联合检测阴性(可接受);若不可行,连续三次细胞学阴性且末次在65岁。
  • 自采标本用于HPV检测时须遵循3年检测间隔。
  • 高危个体(既往异常结果或当前免疫抑制)仍需医生采集标本。

临床怎么用

  • 对平均风险25-65岁个体,可提供自采阴道标本HPV检测作为筛查选项,但应告知医生采集标本为首选。
  • 自采HPV检测阴性后应安排3年复检,避免按5年间隔随访。
  • 退出筛查前需确认60岁和65岁HPV检测阴性或符合替代标准。

局限性

  • 自采标本仅适用于FDA批准的采集装置与HPV检测组合。
  • 自采HPV阳性者多需额外随访步骤。
  • 自采标本长期真实世界有效性数据有限。
  • 高危个体(既往异常或免疫抑制)仍需医生采集标本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This update expands the 2020 American Cancer Society (ACS) cervical cancer screening guideline for average-risk women and individuals with a cervix who are at average risk, to include self-collection for human papillomavirus (HPV) testing and revised guidance for exiting cervical cancer screening. Self-collected vaginal specimens, a method of primary HPV testing, align with the ACS cervical cancer screening guideline. When clinician-collected cervical specimens are used for HPV testing, repeat screening is recommended every 5 years for those with a negative test. For self-collected vaginal specimens, the ACS endorses the following recommendations of the Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee (of which it is a member): (1) primary HPV screening using clinician-collected cervical specimens is preferred, and self-collected vaginal specimens are acceptable for average-risk individuals aged 25-65 years; and (2) repeat testing in 3 years is recommended after a negative result on a self-collected HPV screening test. These recommendations apply only to combinations of collection devices and HPV assays approved by the US Food and Drug Administration for HPV testing in a clinical setting or at home. The rationale notes that the use of self-collected vaginal specimens can overcome barriers to screening for many patients, but most patients who test HPV-positive will require extra follow-up steps, and data on long-term, real-world effectiveness are limited. For certain high-risk individuals, clinician-collected samples are still recommended. Furthermore, in response to high rates of cervical cancer among individuals older than 65 years and with poor implementation of current exiting screening criteria, ACS has amended the 2020 guideline to recommend HPV testing at ages 60 and 65 years, with the last HPV test at an age no younger than 65 years as a requisite to exiting screening. The revised recommendation states: To qualify for discontinuation of screening, the ACS recommends an average-risk woman or an individual with a cervix at average risk have negative primary HPV tests (preferred) or negative co-testing using HPV tests and cytology (acceptable) at ages 60 and 65 years. If primary HPV tests or co-testing are not available, three consecutive negative cytology (Papanicolaou) tests at the recommended screening interval with the last test at age 65 years are acceptable. If self-collected vaginal specimens are used for HPV testing, the 3-year testing interval should be followed. Additional screening exit stipulations relate to women at higher risk because of prior abnormal test results or current immune suppression.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026. PMID: 41342729. doi:10.3322/caac.70041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。